SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat

Article citations


P. D. Delgado-Lopez, V. Martin-Velasco, J. M. Castilla- Diez, A. Rodriguez-Salazar, A. M. Galacho-Harriero and O. Fernandez-Arconada, “Dexamethasone Treatment in Chronic Subdural Haematoma,” Neurocirugia (Astur), Vol. 20, No. 4, 2009, pp. 346-359. doi:10.4321/S1130-14732009000400003

has been cited by the following article:

  • TITLE: Resolution of Chronic Subdural Hematoma after Treatment with Tumor Necrosis Factor Alpha Inhibitor

    AUTHORS: Donald Ross

    KEYWORDS: Chronic Subdural Hematoma, Tumor Necrosis Factor Alpha, Inflammation

    JOURNAL NAME: Neuroscience and Medicine, Vol.2 No.4, December 2, 2011

    ABSTRACT: Background and Importance: Chronic subdural hematomas (cSDH) are a common problem for which solutions remain imperfect. Surgery is effective, but not without risk. Recent data have suggested a role for inflammation in the genesis of cSDH and several reports have documented some benefit to steroid treatment. In this report, a possible role for tumor necrosis factor alpha blockade in the resolution of a multiply recurrent cSDH is described. Clinical Presentation: An 86-year-old man with rheumatoid arthritis treated with infliximab presented with a large, symptomatic, multiloculated cSDH. Infliximab was withheld and craniotomy for evacuation was uncomplicated, but recurrent symptoms were noted and a recurrence was operated upon again several weeks later. Follow up CT showed a second recurrence. The patient requested to go back on his infliximab due to painful arthralgias. After a single dose of 10 mg/kg, follow up CT showed that the cSDH resolved and did not recur. Conclusion: Anti-TNF-alpha treatment with infliximab may have played a role in the resolution of this patient’s cSDH. Further investigation of this possible effect seems warranted.